She Was Told She Was Wasting Her Time. She Changed the World.
In 1985, Katalin Karikó made a choice that would change the world—though it would take forty years for anyone to notice.
She was thirty years old, had a PhD in biochemistry, and believed in an idea that almost everyone thought was insane: messenger RNA could teach human cells how to fight disease.
Communist Hungary wouldn’t let her pursue the research. So she, her husband, and their two-year-old daughter Susan escaped. They sold their Russian-made Lada on the black market for every dollar they could get. Hungary’s government only allowed families leaving the country to carry $100. The rest of their life savings—$1,200—was sewn inside Susan’s teddy bear.
They landed in Philadelphia with nothing but that hidden money and a research position at Temple University that paid $17,000 a year. Four people, including Karikó’s mother who joined them later, lived on that salary.
Then her American dream nearly ended before it began.
Karikó clashed with her supervisor, Robert Suhadolnik. He reported her to immigration authorities. She had to hire a lawyer to fight deportation. A promised job at Johns Hopkins vanished. Suhadolnik continued badmouthing her to other institutions, making it nearly impossible for her to find work.
But she refused to quit.
In 1989, she landed a position at the University of Pennsylvania and continued her research on mRNA. The scientific community wanted nothing to do with it. Grant applications came back rejected again and again. In academia, no grants means no career. RNA was considered unstable, unreliable, a dead end.
When Karikó insisted the problem was with the technique, not the molecule itself, people dismissed her as stubborn or delusional.
Then everything got worse.
In January 1995, she was diagnosed with breast cancer. Her husband got trapped in Hungary for six months due to visa complications, leaving her to fight the disease alone in a foreign country.
At the same time, the University of Pennsylvania gave her an ultimatum: Abandon mRNA research or accept a demotion off the tenure track.
She took the demotion.
Her salary dropped below what the lab technicians earned. Over the next eighteen years, as health insurance and parking costs climbed, her pay barely moved. She was making less in real purchasing power every single year.
She thought about quitting science entirely. Walking away from the molecule she believed in. Finding a normal job that paid a living wage.
But something wouldn’t let her stop.
In 1997, she met Drew Weissman at a photocopier in the university library. They were both printing journal articles. She told him she could make any kind of mRNA. He was intrigued—he’d been trying to develop an HIV vaccine and was frustrated with DNA-based approaches.
They started collaborating in complete obscurity. No prestige. No funding. Even Weissman struggled to get support—it took him ten years to secure his first NIH grant for mRNA research. Anthony Fauci, his former mentor, asked him point-blank: “Why are you wasting your time? Why don’t you do something with potential impact?”
But they kept going.
In 2005, they made the breakthrough that would eventually save millions of lives.
They discovered how to modify mRNA so the human immune system wouldn’t attack it. By substituting one nucleoside with another, they could slip the molecule past the body’s defenses. It was the missing key that made mRNA therapeutics possible.
They wrote up their findings and submitted the paper to Nature and Science—the two most prestigious journals in the scientific world.
Both rejected it. Nature dismissed it as an “incremental contribution.”
The paper was quietly published in a journal called Immunity. Almost nobody read it.
Karikó and Weissman kept working. They founded a small company called RNARx and filed patents. The University of Pennsylvania sold the license to a lab supply company. When Moderna tried to license it weeks later, Karikó had to tell them the rights were no longer available.
Still, the world ignored her work.
In 2013, the University of Pennsylvania forced her out. “I was kicked out from UPenn, was forced to retire,” she later told the Nobel Prize organization. Her supervisors told her she was “not of faculty quality.”
At fifty-eight years old—an age when most scientists are winding down their careers—she took a job at a small German biotech company called BioNTech.
Her former colleagues at Penn laughed at her. “BioNTech doesn’t even have a website,” they said.
She went anyway.
Then 2020 arrived.
COVID-19 swept across the planet. Within months, the technology that had been dismissed and ridiculed for forty years became the foundation of the fastest vaccine development in human history.
BioNTech partnered with Pfizer. Moderna used Karikó and Weissman’s nucleoside modifications. By December 2020, mRNA vaccines were being administered to millions of people worldwide.
The vaccines showed over 90% efficacy. They saved millions of lives. They ended lockdowns. They gave the world a path out of the pandemic.
And they worked because a woman who had been told for forty years that she was wasting her time refused to believe it.
On October 2, 2023, at 3:40 in the morning, Karikó’s phone rang. No number showed on the screen. The voice on the other end told her she’d won the Nobel Prize in Physiology or Medicine.
She thought it was a prank.
It wasn’t. She and Drew Weissman had been awarded the Nobel Prize “for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.”
Within hours, the University of Pennsylvania—the institution that had demoted her, underpaid her for eighteen years, and forced her into retirement by telling her she wasn’t good enough—flooded social media with posts celebrating “Penn’s historic mRNA vaccine research team.”
Twitter immediately flagged the posts as misleading. Karikó hadn’t been affiliated with Penn for a decade. She’d been pushed out.
At her Nobel Prize press conference, Karikó smiled and said Penn should invest in more photocopiers “so researchers have the opportunity to stand around, chitchat, and share their ideas.”
Her daughter Susan—the little girl who crossed the Atlantic in 1985 clutching a teddy bear stuffed with their family’s entire savings—became a two-time Olympic gold medalist in rowing for the United States.
Karikó still has the teddy bear.
She was never promoted at Penn. Never celebrated early in her career. Never believed in because the establishment validated her.
She believed because the science mattered. Because the molecule worked. Because somewhere in the future, people would need it.
And forty years later, when a pandemic threatened to kill millions, when the world desperately needed a solution that didn’t exist yet, the technology was ready.
Because one woman refused to stop.
Think about what this means: Every person who received an mRNA COVID vaccine—billions of people worldwide—benefited from the work of a scientist who was told for forty years she was wasting her time. Who was demoted, underpaid, mocked, and fired. Who was literally forced into retirement because her own university said she wasn’t good enough.
The institution that rejected her now puts her face on their promotional materials.
The colleagues who laughed at her for joining a company “without a website” watched that company develop a vaccine that saved the world.
The scientific establishment that dismissed her 2005 paper as “incremental” now teaches it as one of the most important discoveries of the 21st century.
She didn’t win because she was lucky. She didn’t win because someone finally believed in her.
She won because she believed in the science when absolutely no one else did.
For forty years.
And that belief saved millions of lives.
